Peter Chin

6.5k total citations · 1 hit paper
67 papers, 1.7k citations indexed

About

Peter Chin is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Artificial Intelligence. According to data from OpenAlex, Peter Chin has authored 67 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pathology and Forensic Medicine, 11 papers in Molecular Biology and 11 papers in Artificial Intelligence. Recurrent topics in Peter Chin's work include Multiple Sclerosis Research Studies (23 papers), Polyomavirus and related diseases (5 papers) and Peripheral Neuropathies and Disorders (4 papers). Peter Chin is often cited by papers focused on Multiple Sclerosis Research Studies (23 papers), Polyomavirus and related diseases (5 papers) and Peripheral Neuropathies and Disorders (4 papers). Peter Chin collaborates with scholars based in United States, Switzerland and United Kingdom. Peter Chin's co-authors include Henry Szechtman, Alan E. Fisher, Seymour M. Antelman, Stephen L. Hauser, Paul O’Connor, Emmanuelle Waubant, Mark S. Freedman, Craig H. Smith, Jiameng Zhang and Timothy Vollmer and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Peter Chin

59 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

2009 686 citations Kathleen Hawker, Paul O’Connor et al. Annals of Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Chin United States	18	821	375	279	255	227	67	1.7k
Davide Maimone Italy	25	658 0.8×	469 1.3×	219 0.8×	280 1.1×	197 0.9×	59	1.7k
Anneke van der Walt Australia	23	893 1.1×	400 1.1×	111 0.4×	135 0.5×	111 0.5×	142	1.5k
Carsten Lukas Germany	27	1.2k 1.4×	746 2.0×	430 1.5×	109 0.4×	357 1.6×	111	2.4k
Dorothea Buck Germany	25	1.2k 1.4×	443 1.2×	116 0.4×	429 1.7×	235 1.0×	41	2.5k
Katja Akgün Germany	22	755 0.9×	372 1.0×	77 0.3×	362 1.4×	238 1.0×	82	1.8k
Robert Carruthers Canada	18	583 0.7×	213 0.6×	275 1.0×	87 0.3×	94 0.4×	72	1.4k
Dejan Jakimovski United States	29	2.1k 2.6×	764 2.0×	181 0.6×	288 1.1×	310 1.4×	179	3.0k
Lluís Ramió‐Torrentà Spain	26	1.3k 1.6×	939 2.5×	237 0.8×	109 0.4×	151 0.7×	92	2.8k
María I. Gaitán United States	20	1.5k 1.8×	347 0.9×	79 0.3×	497 1.9×	183 0.8×	45	2.3k
Tobias Granberg Sweden	26	750 0.9×	839 2.2×	260 0.9×	78 0.3×	100 0.4×	84	2.2k

Countries citing papers authored by Peter Chin

Since Specialization

Citations

This map shows the geographic impact of Peter Chin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Chin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Chin more than expected).

Fields of papers citing papers by Peter Chin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Chin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Chin. The network helps show where Peter Chin may publish in the future.

Co-authorship network of co-authors of Peter Chin

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Chin. A scholar is included among the top collaborators of Peter Chin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Chin. Peter Chin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burton, Barbara K., Deepa Rajan, Simon A. Jones, et al.. (2025). An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II. New England Journal of Medicine. 394(1). 39–50.

Wood, Andrew W., et al.. (2025). ZipNN: Lossless Compression for AI Models. 186–198.

Chin, Peter, et al.. (2024). Graphical Learning Optimization and Dimensionality Reduction with Geometric Multi-Resolution Analysis. 1–8.

Wang, Xiao, Wei Jiang, Wei Wang, et al.. (2022). Substitutional Neural Image Compression. OpenBU (Boston University). 11. 97–101. 5 indexed citations

Weber, Verena, et al.. (2022). Semi-supervised Adversarial Text Generation based on Seq2Seq models. 254–262. 1 indexed citations

Chin, Peter, et al.. (2019). MP46-14 VARICOCELE AND MAY-THURNER SYNDROME: THE ETIOLOGICAL LINK. The Journal of Urology. 201(Supplement 4).

Özdemir, Onur, et al.. (2018). Learning to Repair Software Vulnerabilities with Generative Adversarial Networks. Neural Information Processing Systems. 31. 7933–7943. 5 indexed citations

Chin, Peter, et al.. (2018). Tree Structured Multimedia Signal Modeling.. The Florida AI Research Society. 184–188. 1 indexed citations

Wolinsky, Jerry S., Xavier Montalbán, Ludwig Kappos, et al.. (2017). Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial (P4.384). Neurology. 88(16_supplement). 1 indexed citations

10.

Naismith, Robert T., Mark Cascione, Luigi Maria Edoardo Grimaldi, et al.. (2017). Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study (S31.004). Neurology. 88(16_supplement). 2 indexed citations

11.

Chin, Peter & Andrew C. Chan. (2017). Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis. Biochemistry. 57(5). 474–476. 2 indexed citations

12.

Arnold, Douglas L., Amit Bar‐Or, Giancarlo Comi, et al.. (2016). Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002). Neurology. 86(16_supplement). 1 indexed citations

13.

Traboulsee, Anthony, Douglas L. Arnold, Amit Bar‐Or, et al.. (2016). Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004). Neurology. 86(16_supplement). 12 indexed citations

14.

Montalbán, Xavier, Bernhard Hemmer, Kottil Rammohan, et al.. (2015). Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017). Neurology. 84(14_supplement). 2 indexed citations

15.

Radue, Ernst‐Wilhelm, et al.. (2014). Consistent Reduction In The Annualized Rate Of Brain Volume Loss Across Phase 3 Core And Extension Trials Of Fingolimod In Relapsing Multiple Sclerosis (P3.180). Neurology. 82(10_supplement). 1 indexed citations

16.

Bergvall, Niklas, et al.. (2014). Efficacy Of Fingolimod In Pre-Treated Patients With Disease Activity: Pooled Analyses Of FREEDOMS and FREEDOMS II (P3.174). Neurology. 82(10_supplement). 8 indexed citations

17.

Meng, Xiangyi, et al.. (2014). Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing–remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemporary Clinical Trials. 41. 69–74. 9 indexed citations

18.

Meng, Xiangyi, et al.. (2013). Effect of Switching from Intramuscular Interferon b-1a to Fingolimod on Time to Relapse in Patients with Relapsing-Remitting Multiple Sclerosis Enrolled in a 1-Year Extension of TRANSFORMS (P07.107). Neurology. 80(7_supplement). 2 indexed citations

19.

Bergvall, Niklas, Nikolaos Sfikas, Peter Chin, et al.. (2013). Effect of Fingolimod on Confirmed Improvement in Physical Disability: Post-Hoc Analyses of FREEDOMS I and TRANSFORMS (P07.108). Neurology. 80(7_supplement). 1 indexed citations

20.

Hawker, Kathleen, Paul O’Connor, Mark S. Freedman, et al.. (2009). Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial. Annals of Neurology. 66(4). 460–471. 686 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact